DCOY
What one share of Decoy Therapeutics holds
Pharmaceutical Preparations
We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through our proprietary IMP3ACT™ platform.
Decoy Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$40.40 |
|---|---|
| Cash and investments | $15.58 |
| Book value | $8.12 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $133.46 | −$926.00 | $0.00 | −$739.75 | — | $2,568 |
| 2022 | $0.00 | −$1,785 | — | −$993.85 | — | $552.40 |
| 2023 | — | −$461.04 | — | −$472.19 | — | $161.10 |
| 2024 | — | −$69.54 | $0.00 | −$56.44 | — | $15.73 |
| 2025 | — | −$129.10 | $5.95 | −$55.73 | — | $11.07 |